Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2005

View Archived Issues

RG-108 reactivates tumor suppressor genes by reverting epigenetic mutations in cancer cells

In vitro antiangiogenic actions of pasireotide compared to octreotide

Transferrin receptor revealed as a novel cancer target

New data on the antitumor effects and safety of ZD-6474 in solid malignancies

Response to HSPPC-96 is not affected by cytokines in advanced melanoma patients

ADAM33 gene involved in embryonic airway development and determines severity of COPD

QR-333 safely reduces symptoms of diabetic peripheral neuropathy

Pegvisomant treatment benefits patients with acromegaly

Bosentan shows efficacy in stabilizing disease in patients with advanced melanoma

New phase II data supports the use of Rambazole in acne

Snapshots on pregabalin in epilepsy and neuropathic pain

Novagali Pharma completes initial clinical evaluation of proprietary oral paclitaxel

Novartis reports promising phase III data with SPP-100 for hypertension

Cytheris initiates additional phase I/II trial with recombinant interleukin-7

FDA grants full approval to Arimidex for treatment of postmenopausal breast cancer

The Immune Response Corporation reports update on HIV and MS clinical programs

Curis and Procter & Gamble collaborate on hair growth program

NeuTec Pharma to evaluate Mycograb for breast cancer

Tachykinin antagonists prepared and tested at Takeda

Celera begins phase I clinical evaluation of cathepsin S inhibitor for psoriasis

Celtic Pharma acquires worldwide rights to Xerecept

Isis begins phase II development of second-generation antisense drug for high cholesterol

Medicure receives FDA fast track designation for MC-1

Novel antidiabetic agents disclosed in recent patent literature

Pfizer receives nonapprovable letter in U.S. for COX-2 inhibitor for acute pain

UCB's antiepileptic Keppra approved in E.U.

Novartis reports phase III data and update of R&D pipeline

Anti-HEH4 antibodies claimed for bone or cartilage-related disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Sex differences shape gene activity across the human brain
BioWorld
Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
Gilead Sciences patents new GTPase KRAS G12D inhibitors
BioWorld Science
Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.